- Home
- NVS
NVS
Novartis AG
as 07-11-2025 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Upcoming Earnings Alert:
Get ready for potential market movements as Novartis AG NVS prepares to release earnings report on 17 Jul 2025.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.5B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.38 | EPS Growth: | -13.29 |
| 52 Week Low/High: | $96.06 - $124.83 | Next Earning Date: | 07-17-2025 |
| Revenue: | $53,222,000,000 | Revenue Growth: | 11.50% |
| Revenue Growth (this year): | 7.22% | Revenue Growth (next year): | 1.94% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
CNW Group
a day ago
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
GlobeNewswire
2 days ago
Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape
Zacks
2 days ago
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
BioPharma Dive
2 days ago
Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding
PR Newswire
3 days ago
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
PR Newswire
3 days ago
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets
The Wall Street Journal
3 days ago
Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?
Pharma Voice
3 days ago
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.